Henry Schein HSIC · NASDAQ
$86.38 -0.70% (-$0.61)
Summary
49 / 100 · Bulios Score
What speaks for it
- It bought back its own shares for $850.0M in the last fiscal year, 8.8% of its market value.
- It has been profitable 6 years in a row.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share fell by 5.8% a year over the last 3 years.
- Repaying its net debt would take 3.5 years of operating profit.
- Out of every 100 USD of revenue, only 3.0 USD is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 24.1 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 5.4% a year over 5 years. Over the last 3 years it grew by 1.4% a year. For the next fiscal year analysts expect revenue to fall by 0.8%. Earnings per share fell by 5.8% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 70 USD
- Sales and administration 25 USD
- Taxes and other 2.7 USD
- Net profit 3.0 USD
Net profit, industry median (Medical - Distribution) 1.4 USD
Out of every 100 USD of revenue, 3.0 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 7.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 17
- Hold 14
- Sell 3
Today's price within the analysts' price targets
The average target of $92.33 is 6.9% above today's price. 50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2018By product
- Healthcare Distribution 96%
- Technology 3.9%
By region
- UNITED STATES 100%
Healthcare Distribution brings in 96% of revenue. Technology grew fastest, by 9.7% a year.
Segments in detail